



Leadership, Advisor, and Awards

# Senior Management Team



## Robert E. Fallon

President, CEO and Chairman

- Co-founder
- Former Chairman & CEO of a large publicly traded company
- Deeply experienced international leader in finance, technology and education
- Crain's NY Notable Health Care Leader Award 2022
- BA from Ohio University and MBA from Harvard Business School



## Matthew R. Price

Executive VP, COO and Director

- Co-founder, managing Company licensing, strategy, finance and operations since inception
- Responsible for formal collaborations with Pfizer / Merck KGaA and the National Cancer Institute (NCI)
- 2022 Emerging Pharma Leader award (*Pharmaceutical Executive*)
- AB from Princeton University and MBA from Columbia Business School



## Johan Baeck, MD

Chief Medical Officer

- Former SVP of Clinical Development and Medical Affairs at Jounce Therapeutics
- Extensive clinical development and medical affairs experience crossing oncology therapeutic modalities
- Prior roles at Novartis, Immunocore and Abbott
- MD from KU Leuven, Belgium



## Tyler D. Ames, PhD

Senior Vice President of Research and Development

- Leadership of PT-112 research programs and co-inventorship of issued US patents
- Previous post-doctoral fellow at University of California Berkeley
- BS from Worcester Polytechnic Institute and PhD in nucleic acid biochemistry from Yale University



## Hélène Shea, PhD

Vice President of CMC

- Formerly Head of CMC at Saniona
- Roles of ascending responsibility at Johnson Matthey and AMAG Pharmaceuticals
- API leadership for brigatinib (Albrundig®) at Ariad Pharmaceuticals
- PhD in organic chemistry from Dartmouth College



## Brooke Raphael, MS

Vice President of Strategy and Operations

- Various commercial and clinical development positions at Celgene and Intercept Pharmaceuticals
- BS from Tufts University, MS in biomedical engineering from Columbia University and MBA from Columbia Business School



## Stanley J. Musial, CPA, MBA

Chief Financial Officer

- 25 years experience building stakeholder value, raising capital, M&A, and commercial launch execution
- Former CFO for multiple private and public biotechnology companies
- MBA in finance, Temple University; BS in accounting, Pennsylvania State University



## Manny Lazaro

Head of Clinical Operations

- Thirty years of clinical research development, operational and executive experience
- Former SVP Development Operations, Jounce Therapeutics
- Roles of increasing responsibility at Cubist Therapeutics, Forma Therapeutics and Vertex
- BS from Univ. of Massachusetts Boston



## Joseph O'Donnell, MD

Senior Medical Director

- Former Chief of Oncology, White River Junction VA Hospital; Associate Dir., Norris Cotton Cancer Ctr
- Professor of Medicine and Psychiatry at Geisel School of Medicine at Dartmouth
- MD from Harvard Medical School
- Company SAB member since inception

# Scientific Advisory Board



## Daniel D. Von Hoff, MD, FACP; Head of SAB

- Distinguished Professor, Translational Genomics Research Institute
- Former President, American Association of Cancer Research (AACR); Karnofsky Memorial Award Winner (ASCO)
- Professor of Medicine, Mayo Clinic and Univ. of Arizona
- Inaugural recipient of the AACR's Von Hoff Award



## Daniel D. Karp, MD

- Professor, Investigational Cancer Therapeutics Department, The University of Texas MD Anderson Cancer Center
- MD Anderson co-Principal Investigator of the University of Texas Houston Clinical Translational Science Award (CTSA) grant



## Howard I. Scher, MD

- Head, Biomarker Development Program; D. Wayne Calloway Chair in Urologic Oncology, Memorial Sloan Kettering Cancer Center
- Chairman, Scientific Oversight Committee, The Prostate Cancer Clinical Trials Consortium
- Founder / Chair: Prostate Cancer Working Group



## Lorenzo Galluzzi, PhD

- Head of the Galluzzi Lab and Assistant Professor of Cell Biology in Radiation Oncology at Weill Cornell Medical College
- Associate director of the European Academy for Tumor Immunology
- Founding member of the European Research Institute for Integrated Cellular Pathology
- One of the pioneers in the field of immunogenic cancer cell death (ICD)



## José Jimeno, MD, PhD

- VP Global Head, Virology and Inflammation at PharmaMar; former Chief Medical Officer, Promontory Therapeutics
- Former VP of Clinical Development at PharmaMar, including the development of Yondelis® and Aplidine®
- MD, University of Zaragoza, Spain; PhD, University of Barcelona




## J. Kay Noel, PhD

- Chief Operating Officer, Collaborative Medicinal Development
- Former co-founder and COO, OncoEthix, S.A., licensed to Merck



# Exceptional Prostate Cancer Clinical Advisory Group



**Howard I. Scher, MD (co-lead PI)**  
Memorial Sloan Kettering Cancer Center

- Co-Chair, Center for Mechanism Based Therapy
- Head of the Biomarker Development Initiative
- D. Wayne Calloway Chair in Urologic Oncology
- Founder/Chair, Prostate Cancer Working Group



**Alan H. Bryce, MD (co-lead PI)**  
Mayo Clinic

- Associate Professor of Medicine
- Chair, Genitourinary Oncology, Mayo Clinic system
- Chair, Division of Hematology / Medical Oncology, Mayo Clinic Arizona



**Daniel D. Karp, MD**  
MD Anderson Cancer Center

- Professor, Investigational Cancer Therapeutics Department
- MD Anderson co-Principal Investigator of the University of Texas Houston Clinical Translational Science Award (CTSA) grant



**Dana Rathkopf, MD**  
Memorial Sloan Kettering Cancer Center

- Associate Professor of Medicine (WCMC)
- Attending Physician, MSKCC
- Chair, MSKCC Research Council
- ASCO Merit Award / PCF Young Investigator Award



**Scott T. Tagawa, MD, MS, FACP**  
Weill Cornell Medical College

- Professor of Medicine and Urology, Weill Cornell Medicine
- Attending Physician, New York Presbyterian Weill Cornell Medical Center



**Karim Fizazi, MD, PhD**  
Institut Gustave Roussy

- Medical Oncologist, IGR
- Professor of Oncology, University of Paris-Saclay
- Founder, Prostate Cancer Consortium in Europe (PEACE)
- Winner, ESMO Award 2022

# Industry Veterans Serving as Independent Board Directors



**Elizabeth Tallett**

**Chairperson, Elevance Health**

- Over 35 years in strategic leadership and operational roles in worldwide biopharmaceutical and consumer products industries
- Prior senior positions include Principal of Hunter Partners, as President and CEO of Transcell Technologies Inc., and as President of Centocor Pharmaceuticals (acquired by JNJ), where she was responsible for antibody drug development

*Additionally, she serves on the Board of:*

- Elevance Health (NYSE: ELV, formerly Anthem Health), the second largest health insurer, where she serves as Chair
- Moderna (Nasdaq: MRNA), as audit committee Chair
- Qiagen (NYSE: QGEN)



**Sebastian Guth, PhD**

**President, Bayer Pharmaceuticals, Americas Region**

- Over 20 years of experience in pharmaceuticals and medtech
- President of Bayer's Pharmaceuticals business for the Americas, and member of the Executive Management Committee of Bayer AG
- MBA from the WHU Otto Beisheim Graduate School of Management and PhD in Management Sciences from Berlin University of Technology

*Additionally, he serves on the Board of:*

- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Biotechnology Innovation Organization (BIO)
- Children's Aid (Pension & Personnel and Strategy & Excellence Committee), one of America's oldest and largest children's nonprofits.



# Biotech Breakthrough Awards Winner



Annual Awards Program Recognizes Innovation in the  
Global Life Sciences and Biotechnology Industry

**Promontory Therapeutics and PT-112 were selected  
among 1,350 nominations across all categories as:**

***“Cancer Immunology Solution of the Year”***